Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip (NYSE:DHR)
· seekingalpha.com
Danaher delivered Q2 revenue of $6.3B, beating estimates and segment growth across Biotechnology, Diagnostics, and Life Sciences. Read more on DHR stock here.
Danaher Corporation ( DHR ) just reported its Q2 earnings , so I wanted to go through them in more detail and give some comments on the outlook and why I don’...